Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema.
The effect of ketorolac tromethamine 0.5% ophthalmic solution (a new nonsteroidal anti-inflammatory agent) treatment was compared to placebo treatment in patients with chronic, angiographically proven aphakic or pseudophakic cystoid macular edema (visual acuity less than or equal to 20/40 for six months) during a three- to four-month double-masked, randomized study. Twenty-six patients completed this study without significant ocular or systemic toxicity. The improved distance visual acuity observed in the ketorolac treatment group (8/13 patients) was statistically different from the improved vision observed in the placebo treated group (1/13 patients) (P = .005). No patient on a regimen of ketorolac therapy had a significant decrease in Snellen distance visual acuity while on treatment, but two patients in the placebo group demonstrated a decrease in visual acuity of two lines or more. Fluorescein angiography was consistent with changes in visual acuity.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001036:Aphakia, Postcataract / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D020911:Ketorolac Tromethamine; D007910:Lenses, Intraocular; D008269:Macular Edema / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D011758:Pyrroles / Q000627:therapeutic use*; D011897:Random Allocation; D013997:Time Factors; D014046:Tolmetin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014325:Tromethamine / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011758:Pyrroles; D014325:Tromethamine; D020911:Ketorolac Tromethamine; D014046:Tolmetin